Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
PRINCETON, N.J., May 03, 2017 -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) being held May 6 - 9, 2017 in San Diego, CA.
The SECURE study evaluated the clinical benefit of the investigational transdermal contraceptive patch AG200-15, known as Twirla®, in a diverse, real-world population of women reflective of current weight trends in the United States. The ePoster will include efficacy and safety findings for the overall population and pre-specified body mass index (BMI) categories, in addition to results on the bleeding profile that have not previously reported.
The presentation details are as follows:
| Poster Title: | Results from the SECURE Trial, a Phase 3 Study of the AG200-15 |
| Investigational Transdermal Contraceptive Patch | |
| Poster ID: | 22A |
| Poster Session: | ePoster Session A |
| Room: | Ballroom 20A |
| Date and Time: | Saturday, May 6, 2017 |
| Time: | 11:00 am – 12:00 pm PT |
| Presenter: | Anita Nelson, MD, Professor and Chair, Obstetrics and Gynecology, |
| College of Osteopathic Medicine of the Pacific |
For more information, please visit the company website at www.agiletherapeutics.com.
About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Source: Agile Therapeutics
Investor Relations Contact: Mary Coleman Agile Therapeutics 609-356-1921 [email protected] Media Relations Contact: Glenn Silver Lazar Partners Ltd. 646-871-8485 [email protected]
